recall radarNODEJAVASCRIPT.COM

Biologic or vaccine recall notices

259notices on file
4publishing bodies
6recorded as Class 1

Notices

Most recently updated first, out of 259 notices in this category.

Sanofi-Aventis Canada Inc. recalling certain insulin pens and cartridges
Communications and Public Affairs Branch · 2026-09-25 · Class 1
Limited number of Sarclisa single use vials may have been frozen during shipment
Drugs and health products · 2026-09-25 · Class 1
IMAAVY: Affected lots may contain glass particles
Drugs and health products · 2026-09-21 · Class 2
TZIELD (teplizumab) and the Risk of Viral Reactivation
Marketed health products · 2026-09-14 · Class not stated
Two lots of Omnitrope injectable human growth hormone recalled due to cracked cartridges
Communications and Public Affairs Branch · 2026-07-08 · Class 1
IXCHIQ (chikungunya vaccine, live, attenuated) and the Risk of Serious Adverse Reactions i
Marketed health products · 2026-03-09 · Class not stated
Important Safety Information on Yescarta (axicabtagene ciloleucel) and the Risk of Cerebra
Marketed health products · 2025-12-10 · Class not stated
Ozempic Solution: Cracked glass cartridges
Drugs and health products · 2025-10-31 · Class 2
Important Safety Information on CRYSVITA (burosumab) and the Risk of Severe Hypercalcemia
Marketed health products · 2025-08-25 · Class not stated
YF-Vax powder for solution; Cracked vials
Drugs and health products · 2025-08-07 · Class 2
Gamunex solution; may cause allergic / hypersensitivity type reaction
Drugs and health products · 2025-06-19 · Class 3
Kimmtrak Solution; Out of specification (in-vitro potency assay)
Drugs and health products · 2025-06-16 · Class 2
Neupogen vials; Out of specification (Stability)
Drugs and health products · 2025-03-27 · Class 3
Panhematin powder for solution: Sterility concern
Drugs and health products · 2024-09-13 · Class 1
Tisseel Kit; Out-of-specification (Dissolution)
Drugs and health products · 2024-05-23 · Class 2
Cord blood banked at the Canadian Cord Blood bioRepository in Edmonton, Alberta, may pose
Communications and Public Affairs Branch · 2023-11-01 · Class not stated
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Fai
Marketed health products · 2023-01-17 · Class not stated
Allergenic extract non pollens (Peanut allergy): False negative for skin test
Drugs and health products · 2022-12-14 · Class 1
COMIRNATY Original & Omicron BA.4/BA.5 Bivalent Vaccine with English-only Vial and Carton
Marketed health products · 2022-12-09 · Class not stated
SPIKEVAX Bivalent (Original / Omicron BA.4/5) (elasomeran/davesomeran) COVID-19 Vaccine wi
Marketed health products · 2022-11-18 · Class not stated
Allergenic extract non pollens (Peanut allergy): False negative for skin test
Drugs and health products · 2022-11-15 · Class 1
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Fai
Marketed health products · 2022-10-26 · Class not stated
BOOSTRIX: Syringes may be cracked in affected lot.
Drugs and health products · 2022-10-07 · Class 2
COMIRNATY Original & Omicron BA.4/BA.5 Bivalent Vaccine with English-only Vial and Carton
Marketed health products · 2022-10-07 · Class not stated
ZOLGENSMA (onasemnogene abeparvovec) and Fatal Cases of Acute Liver Failure
Marketed health products · 2022-09-12 · Class not stated
COMIRNATY (COVID-19 Vaccine, mRNA, also referred to as Pfizer-BioNTech COVID-19 Vaccine):
Marketed health products · 2022-09-09 · Class not stated
Distribution of SPIKEVAX Bivalent (elasomeran/imelasomeran) COVID-19 Vaccine with English-
Marketed health products · 2022-09-02 · Class not stated
IMVAMUNE Vaccine: Updated Storage Conditions and Shelf Life
Marketed health products · 2022-07-29 · Class not stated
Distribution of a New Presentation of SPIKEVAX (elasomeran) COVID-19 Vaccine (0.10 mg/mL i
Marketed health products · 2022-06-06 · Class not stated
COMIRNATY (COVID-19 Vaccine, mRNA, also referred to as Pfizer-BioNTech COVID-19 Vaccine):
Marketed health products · 2022-05-09 · Class not stated
Sotrovimab for Injection - Risk of Treatment Failure due to Circulation of SARS-CoV-2 Omic
Marketed health products · 2022-04-14 · Class not stated
Shelf Life Extension for the SPIKEVAX (elasomeran) COVID-19 Vaccine with Printed Expiry Da
Marketed health products · 2022-01-11 · Class not stated
COMIRNATY (COVID-19 Vaccine, mRNA, also referred to as Pfizer-BioNTech COVID-19 Vaccine):
Marketed health products · 2021-11-19 · Class not stated
Distribution of SPIKEVAX (elasomeran) COVID-19 Vaccine with English-only Vial and Carton L
Marketed health products · 2021-11-10 · Class not stated
Health Canada is updating the labels of the Janssen and Vaxzevria (AstraZeneca) COVID-19 v
Communications and Public Affairs Branch · 2021-11-09 · Class not stated
Importation of Janssen COVID-19 Vaccine with European Union (EU) English-only Vial and Car
Marketed health products · 2021-11-05 · Class not stated
Authorization of Sotrovimab for Injection for Use in Relation to the COVID-19 Pandemic
Marketed health products · 2021-10-04 · Class not stated
One lot of the hypoglycemia treatment Glucagon recalled as it may pose serious health risk
Communications and Public Affairs Branch · 2021-09-25 · Class not stated
Health Canada updates Pfizer-BioNTech COVID-19 vaccine label to reflect very rare reports
Communications and Public Affairs Branch · 2021-08-06 · Class not stated
Health Canada updates Pfizer-BioNTech and Moderna COVID-19 vaccine labels to include infor
Communications and Public Affairs Branch · 2021-06-30 · Class not stated
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome
Marketed health products · 2021-06-29 · Class not stated
Health Canada issues label change on the AstraZeneca and COVISHIELD COVID-19 vaccines
Communications and Public Affairs Branch · 2021-06-29 · Class not stated
Importation of COVID-19 Vaccine Moderna with up to 15 Doses per Vial and English-only Vial
Marketed health products · 2021-06-14 · Class not stated
Bamlanivimab - Potential Risk of Treatment Failure Due to Circulation of Resistant SARS-Co
Marketed health products · 2021-04-28 · Class not stated
Janssen COVID-19 Vaccine and the Risk of Thrombosis with Thrombocytopenia
Marketed health products · 2021-04-26 · Class not stated
Importation of Janssen COVID-19 Vaccine with Two Types of English-only Vial and Carton Lab
Marketed health products · 2021-04-26 · Class not stated
Importation of AstraZeneca COVID-19 Vaccine with English-only Vial and Carton Labels (US-L
Marketed health products · 2021-03-31 · Class not stated
AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Thrombosis with Thrombocytopenia
Marketed health products · 2021-03-24 · Class not stated
Pfizer-BioNTech COVID-19 Vaccine: Updated Storage and Transportation Conditions
Marketed health products · 2021-03-08 · Class not stated
Authorization of Janssen COVID-19 Vaccine with English-only Vial and Carton Labels
Marketed health products · 2021-03-08 · Class not stated
Authorization of COVISHIELD with English-only Vial and Carton Labels
Marketed health products · 2021-03-01 · Class not stated
Authorization of AstraZeneca COVID-19 Vaccine with English-only Vial and Carton Labels
Marketed health products · 2021-03-01 · Class not stated
COVID-19 Vaccine Moderna: Updated English-only Global Vial and Carton Labels and Post-Mark
Marketed health products · 2021-02-22 · Class not stated
Pfizer-BioNTech COVID-19 Vaccine: Updated Dosage and Administration and Post-Market Advers
Marketed health products · 2021-02-09 · Class not stated
Authorization of Moderna COVID-19 Vaccine with English-only Vial and Carton Labels
Marketed health products · 2020-12-23 · Class not stated
Authorization of Bamlanivimab with English-only Labels for Use in Relation to the COVID-19
Marketed health products · 2020-12-18 · Class not stated
Pfizer-BioNTech COVID-19 vaccine: Health Canada recommendations for people with serious al
Communications and Public Affairs Branch · 2020-12-12 · Class not stated
Authorization of Pfizer-BioNTech COVID-19 Vaccine with English-only Carton and Vial Labels
Marketed health products · 2020-12-12 · Class not stated
Clinical trial looking at the potential use of convalescent plasma to treat COVID-19
Communications and Public Affairs Branch · 2020-05-01 · Class not stated
Clinical management support: Known interference between Hemlibra® (emicizumab injection) a
Marketed health products · 2020-04-17 · Class not stated
Health Canada clarifies position on Platelet Rich Plasma treatments
Communications and Public Affairs Branch · 2019-07-26 · Class not stated
PrBENLYSTA (belimumab) - Increased Risk of Serious Depression, Suicidal Ideation or Behavi
Marketed health products · 2019-04-04 · Class not stated
DARZALEX (daratumumab) and Hepatitis B Virus Reactivation
Marketed health products · 2019-03-25 · Class not stated
TECENTRIQ® (atezolizumab) - Risk of Immune-Related Myositis
Marketed health products · 2019-03-13 · Class not stated
LARTRUVO (olaratumab) - New clinical trial information important to prescribing decisions
Marketed health products · 2019-01-30 · Class not stated
XOFIGO® (radium Ra 223 dichloride) - Increased Incidence of Fractures and Trend for Increa
Marketed health products · 2018-11-08 · Class not stated
TECENTRIQ® (atezolizumab) - Risk of Immune-Related Nephritis
Marketed health products · 2018-09-18 · Class not stated
Several GlaxoSmithKline Inc. vaccines: Potential Risk of Underdosing
Marketed health products · 2018-05-01 · Class not stated
ZINBRYTA (daclizumab beta) - Voluntary Withdrawal in Canada due to Risk of Encephalitis
Marketed health products · 2018-03-16 · Class not stated
Shortage of Erwinase for Injection and Replacement with UK Labelled Stock
Marketed health products · 2018-02-27 · Class not stated
TECENTRIQ (atezolizumab) - Risk of Myocarditis
Marketed health products · 2018-02-14 · Class not stated
Cord blood banked at the Cord Blood Bank of Canada can be used only by the donor
Communications and Public Affairs Branch · 2017-10-17 · Class not stated
Erwinase for Injection - Shortage
Marketed health products · 2017-07-12 · Class not stated
Pg 8528/Pg 8527/Pg 8535/ Pg 8536 Washer-Disinfectors
Medical devices · 2017-05-31 · Class 3
ARANESP - Risk of Severe Skin Reactions: Stevens-Johnson Syndrome and Toxic Epidermal Necr
Marketed health products · 2017-05-05 · Class not stated
Erwinase for Injection - Shortage and Replacement with UK Labelled Stock
Marketed health products · 2017-05-03 · Class not stated
Erwinase for Injection - Replacement with UK Labelled Stock
Marketed health products · 2017-04-12 · Class not stated
KEYTRUDA (pembrolizumab) - Risk of Severe Skin Reactions: Stevens-Johnson Syndrome and Tox
Marketed health products · 2017-03-20 · Class not stated
Erwinase for Injection - Special Handling Instructions
Marketed health products · 2017-02-07 · Class not stated
Erwinase for Injection - Shortage and Special Handling Instructions
Marketed health products · 2017-01-09 · Class not stated
Direct-acting antivirals, used for hepatitis C, may reactivate hepatitis B
Communications and Public Affairs Branch · 2016-12-01 · Class not stated
SOLIRIS (eculizumab) - Increased Risk of Hemolysis or Low Hemoglobin with Serogroup B Meni
Marketed health products · 2016-10-25 · Class not stated
Erwinase for Injection - Shortage and Replacement with UK Labelled Stock
Marketed health products · 2016-09-16 · Class not stated
ERWINASE (Erwinia L-asparaginase) for Injection - Replacement with UK Labelled Stock and S
Marketed health products · 2016-08-02 · Class not stated
Information Update - Gardasil vaccine safety studies show no new risks
Communications and Public Affairs Branch · 2015-12-09 · Class not stated
Humalog (insulin lispro) KwikPen 200 Units/mL - Information on Correct Use to Minimize Med
Marketed health products · 2015-09-14 · Class not stated
STELARA (ustekinumab) - Risk of Rare Serious Skin Conditions - For Health Professionals
Marketed health products · 2014-11-21 · Class not stated
STELARA (ustekinumab) - Risk of Rare Serious Skin Conditions - For the Public
Marketed health products · 2014-11-21 · Class not stated
YERVOY 200 mg/40 mL (5 mg/mL) (Ipilimumab for injection), single-use vial - Recall of 2 Lo
Marketed health products · 2014-10-18 · Class not stated
Safety information on the risk of blood clots with immunoglobulin products
Communications and Public Affairs Branch · 2014-10-09 · Class not stated
Non-Hyperimmune Immunoglobulin Products - Changes to Canadian Product Monographs - Notice
Marketed health products · 2014-10-09 · Class not stated
ARZERRA (ofatumumab) - Fatal Infusion Reaction Reported in a Patient with Chronic Lymphocy
Marketed health products · 2014-08-06 · Class not stated
ARZERRA (ofatumumab) - Fatal Infusion Reaction Reported in a Patient with Chronic Lymphocy
Marketed health products · 2014-08-06 · Class not stated
VECTIBIX (panitumumab) - Rare Cases of Stevens-Johnson Syndrome and Toxic Epidermal Necrol
Marketed health products · 2014-05-27 · Class not stated
VECTIBIX (panitumumab) - Rare Cases of Stevens-Johnson Syndrome and Toxic Epidermal Necrol
Marketed health products · 2014-05-27 · Class not stated
BENLYSTA (belimumab) - Progressive Multifocal Leukoencephalopathy Reported in Patients - F
Marketed health products · 2014-04-28 · Class not stated
BENLYSTA (belimumab) - Progressive Multifocal Leukoencephalopathy Reported in Patients - F
Marketed health products · 2014-04-28 · Class not stated
Neupogen (filgrastim) and Neulasta (pegfilgrastim) - Risk of Capillary Leak Syndrome - For
Marketed health products · 2014-04-10 · Class not stated
Neupogen (filgrastim) and Neulasta (pegfilgrastim) - Risk of Capillary Leak Syndrome - For
Marketed health products · 2014-04-10 · Class not stated
System 1 Base 100/120v (2013-02-20)
Medical devices · 2014-03-18 · Class 2
ARZERRA (ofatumumab) - Recommendations to Screen, Monitor and to Manage Hepatitis B Virus
Marketed health products · 2014-01-27 · Class not stated
ARZERRA (ofatumumab) - Recommendations to Screen, Monitor and to Manage Hepatitis B Virus
Marketed health products · 2014-01-27 · Class not stated
Kadcyla (trastuzumab emtansine) and Herceptin (trastuzumab) - Potential Risk for Medicatio
Marketed health products · 2013-10-09 · Class not stated
RITUXAN (rituximab) - Hepatitis B Virus (HBV) Recurrence in Patients: Updates on Screening
Marketed health products · 2013-07-29 · Class not stated
RITUXAN (rituximab) - Hepatitis B Virus (HBV) Recurrence in Patients: Updates on Screening
Marketed health products · 2013-07-29 · Class not stated
Cathflo (alteplase) - Particulate matter observed in some vials: additional instructions f
Marketed health products · 2013-05-10 · Class not stated
Avastin (bevacizumab) - Cases of Necrotizing Fasciitis Reported - For the Public
Marketed health products · 2013-05-02 · Class not stated
Avastin (bevacizumab) - Cases of Necrotizing Fasciitis Reported - For Health Professionals
Marketed health products · 2013-05-02 · Class not stated
RITUXAN (rituximab) - Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome - For the Pu
Marketed health products · 2013-02-25 · Class not stated
RITUXAN (rituximab) - Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome - For Health
Marketed health products · 2013-02-25 · Class not stated
AGRIFLU and FLUAD - Health Canada Lifts the Suspension of Distribution of these Seasonal F
Marketed health products · 2012-11-09 · Class not stated
Infanrix Hexa - Voluntary Recall of Vaccine Due to Potential Microbiological Contamination
Marketed health products · 2012-11-02 · Class not stated
Voluntary Suspension of Flu Vaccines (Agriflu and Fluad) Lifted
Communications and Public Affairs Branch · 2012-10-31 · Class not stated
Novartis Suspends Distribution of Seasonal Flu Vaccines Agriflu and Fluad in Canada as a P
Communications and Public Affairs Branch · 2012-10-26 · Class not stated
TYPHIM Vi (Salmonella typhi Vi Capsular Polysaccharide Vaccine) - Voluntary Recall of Vi P
Marketed health products · 2012-10-04 · Class not stated
TYPHIM Vi (Salmonella typhi Vi Capsular Polysaccharide Vaccine) - Voluntary Recall of Vi P
Marketed health products · 2012-10-04 · Class not stated
ImmuCyst [Bacillus Calmette-Guérin (BCG), sub strain Connaught] - Supply status - For Heal
Marketed health products · 2012-07-16 · Class not stated
Sanofi Pasteur recalls tuberculosis (BCG) vaccine
Communications and Public Affairs Branch · 2012-06-30 · Class not stated
HepaGam B [Hepatitis B Immune Globulin (Human) Injection] - Theoretical Risk of Thrombotic
Marketed health products · 2012-06-14 · Class not stated
HepaGam B [Hepatitis B Immune Globulin (Human) Injection] - Theoretical Risk of Thrombotic
Marketed health products · 2012-06-14 · Class not stated
Privigen, Immune Globulin Intravenous (Human) - Association of Hemolysis Following Adminis
Marketed health products · 2012-06-01 · Class not stated
Privigen, Immune Globulin Intravenous (Human) - Association of Hemolysis Following Adminis
Marketed health products · 2012-06-01 · Class not stated
Xgeva (denosumab) - Risk of Severe Symptomatic Hypocalcemia, Including Fatal Cases - For t
Marketed health products · 2012-05-31 · Class not stated
Xgeva (denosumab) - Risk of Severe Symptomatic Hypocalcemia, Including Fatal Cases - For H
Marketed health products · 2012-05-31 · Class not stated
Benlysta (belimumab) - Association with Hypersensitivity and Infusion Reactions - For Heal
Marketed health products · 2012-05-08 · Class not stated
AVASTIN (bevacizumab) - Reports of Cases of Severe Eye Inflammation Leading to Blindness F
Marketed health products · 2011-12-07 · Class not stated
Avastin (bevacizumab) - Health Canada has Suspended Approval for Use in Metastatic Breast
Marketed health products · 2011-11-29 · Class not stated
Avastin (bevacizumab) - Higher Incidence of New Cases of Ovarian Failure Observed in Preme
Marketed health products · 2011-11-14 · Class not stated
XIGRIS [drotrecogin alfa (activated)] - Worldwide Withdrawal - Notice to Hospitals
Marketed health products · 2011-10-28 · Class not stated
XIGRIS [drotrecogin alfa (activated)] - Worldwide Withdrawal - For Health Professionals
Marketed health products · 2011-10-28 · Class not stated
XIGRIS [drotrecogin alfa (activated)] – Worldwide Withdrawal – For the Public
Marketed health products · 2011-10-28 · Class not stated
Xigris (drotrecogin alfa) withdrawn worldwide
Communications and Public Affairs Branch · 2011-10-25 · Class not stated
Trasylol (aprotinin) - Important New Safety Information - Notice to Hospitals
Marketed health products · 2011-09-21 · Class not stated
Trasylol (aprotinin) – Important New Safety Information – For the Public
Marketed health products · 2011-09-21 · Class not stated
Potential dangers of using donor semen from questionable sources
Communications and Public Affairs Branch · 2011-08-29 · Class not stated
RITUXAN (rituximab) - Fatal Infusion Related Reactions in Patients with Rheumatoid Arthrit
Marketed health products · 2011-06-07 · Class not stated
Vivaglobin [Immune Globulin Subcutaneous (Human)] - Risk of Thrombotic Events (Blood Clots
Marketed health products · 2011-04-14 · Class not stated
IXIARO Japanese Encephalitis Vaccine (inactivated, adsorbed) - Recall of Lot JEV09L37C - F
Marketed health products · 2011-03-16 · Class not stated
IXIARO Japanese Encephalitis Vaccine (inactivated, adsorbed) - Recall of Lot JEV09L37C - F
Marketed health products · 2011-03-16 · Class not stated
PEGETRON REDIPEN (peginterferon alfa-2b) - Recall of Triad Group Alcohol Prep Pads, Alcoho
Marketed health products · 2011-02-04 · Class not stated
Important information regarding semen donation
Communications and Public Affairs Branch · 2010-12-07 · Class not stated
Innohep (tinzaparin sodium) - Updated Safety Information on Use in Elderly Patients with R
Marketed health products · 2010-10-19 · Class not stated
Innohep (tinzaparin sodium) - Updated Safety Information on Use in Elderly Patients with R
Marketed health products · 2010-10-19 · Class not stated
Pegetron - Important Information Regarding Quality, Safety and Supply - For Health Profess
Marketed health products · 2010-10-12 · Class not stated
ACTEMRA (tocilizumab) - Risk of Fatal Anaphylaxis - For Health Professionals
Marketed health products · 2010-09-17 · Class not stated
ACTEMRA (tocilizumab) - Risk of Fatal Anaphylaxis - For the Public
Marketed health products · 2010-09-17 · Class not stated
Delivery of Topical Hemostatic Agents Using Spray Devices - Association with Air/Gas Embol
Marketed health products · 2010-08-27 · Class not stated
AVASTIN (bevacizumab) - Association with Allergic Reactions - For Health Professionals
Marketed health products · 2010-08-23 · Class not stated
AVASTIN (bevacizumab) - Association with Allergic Reactions - For the Public
Marketed health products · 2010-08-23 · Class not stated
Rotarix - Presence of Porcine Circovirus Type 1 (PCV-1) - For Health Professionals
Marketed health products · 2010-07-30 · Class not stated
RotaTeq - Presence of Porcine Circovirus (PCV) DNA
Marketed health products · 2010-07-30 · Class not stated
Tysabri (natalizumab) - New Safety Information Regarding Progressive Multifocal Leukoencep
Marketed health products · 2010-05-17 · Class not stated
TYSABRI (natalizumab) - New Safety Information Regarding Progressive Multifocal Leukoencep
Marketed health products · 2010-05-17 · Class not stated
Important Information Regarding Rotavirus Vaccines: Rotarix and RotaTeq
Communications and Public Affairs Branch · 2010-05-07 · Class not stated
New Expiry Date for Unused Adjuvanted H1N1 Vaccine (Arepanrix)
Communications and Public Affairs Branch · 2010-04-09 · Class not stated
WinRho SDF (Rho(D) Immune Globulin (Human)) - Association with Intravascular Hemolysis in
Marketed health products · 2010-03-24 · Class not stated
WinRho SDF (Rho(D) Immune Globulin (Human)) - Association with Intravascular Hemolysis in
Marketed health products · 2010-03-24 · Class not stated
Cerezyme (imiglucerase for injection) - Supply and Recommendations for Restarting Cerezyme
Marketed health products · 2009-12-29 · Class not stated
Archived - Cerezyme (imiglucerase for injection) - Supply and Recommendations for Restarti
Marketed health products · 2009-12-29 · Class not stated
Thyrogen (thyrotropin alfa for injection): Caution with Preparation and Administration - F
Marketed health products · 2009-12-09 · Class not stated
Cerezyme (imiglucerase for injection), Fabrazyme (agalsidase beta), Myozyme (alglucosidase
Marketed health products · 2009-12-09 · Class not stated
Heparin - Decreased Potency as a Result of New United States Pharmacopeia (USP) Standards
Marketed health products · 2009-11-26 · Class not stated
Authorization for Sale and Post-Market Activities for Arepanrix H1N1 Vaccine - For Health
Marketed health products · 2009-11-16 · Class not stated
Association of Rituxan (rituximab) with Progressive Multifocal Leukoencephalopathy (PML) -
Marketed health products · 2009-10-23 · Class not stated
Archived - Association of Rituxan (rituximab) with Progressive Multifocal Leukoencephalopa
Marketed health products · 2009-10-23 · Class not stated
Archived - Market withdrawal of Raptiva (efalizumab) in Canada- For the Public
Marketed health products · 2009-06-17 · Class not stated
Important Safety Information Concerning Pre-filled Saline and Heparin Syringes Manufacture
Marketed health products · 2009-05-06 · Class not stated
Archived - Association of Enbrel (etanercept) with Histoplasmosis and Other Invasive Funga
Marketed health products · 2009-04-23 · Class not stated
Archived - Synagis (palivizumab) - Abbott Laboratories Limited
Marketed health products · 2009-02-23 · Class not stated
Archived - Suspension of marketing of Raptiva (efalizumab) in Canada - For the Public
Marketed health products · 2009-02-20 · Class not stated
New Safety Information Regarding Progressive Multifocal Leukoencephalopathy (PML) Associat
Marketed health products · 2009-02-18 · Class not stated
Archived - New Safety Information Regarding Progressive Multifocal Leukoencephalopathy (PM
Marketed health products · 2009-02-18 · Class not stated
Additional safety information related to Botox and Botox Cosmetic (botulinum toxin type A)
Marketed health products · 2009-01-13 · Class not stated
Association of Raptiva (efalizumab) with serious infections, including progressive multifo
Marketed health products · 2008-12-30 · Class not stated
Archived - Association of Raptiva (efalizumab) with serious infections, including progress
Marketed health products · 2008-12-30 · Class not stated
Reports of Eye Inflammation, Endophthalmitis, and Toxic Anterior Segment Syndrome (TASS) F
Marketed health products · 2008-12-19 · Class not stated
Archived - Reports of Eye Inflammation, Endophthalmitis, and Toxic Anterior Segment Syndro
Marketed health products · 2008-12-19 · Class not stated
Infection-related deaths were reported with the use of MabCampath (alemtuzumab) following
Marketed health products · 2008-11-21 · Class not stated
Archived - Infection-related deaths were reported with the use of MabCampath (alemtuzumab)
Marketed health products · 2008-11-21 · Class not stated
Increased risk of marked hepatic enzyme elevations in patients taking SOMAVERT (pegvisoman
Marketed health products · 2008-06-10 · Class not stated
Archived - Increased risk of marked hepatic enzyme elevations in patients taking SOMAVERT
Marketed health products · 2008-06-10 · Class not stated
New Safety Information Regarding Liver Injury and Hypersensitivity Associated with TYSABRI
Marketed health products · 2008-06-06 · Class not stated
Archived - New Safety Information Regarding Liver Injury and Hypersensitivity Associated w
Marketed health products · 2008-06-06 · Class not stated
Important Safety Information on HEPARIN - Notice to Hospitals
Marketed health products · 2008-03-28 · Class not stated
Archived - Review Determines Measles, Mumps and Rubella Vaccine Lots Can be Released for U
Communications and Public Affairs Branch · 2008-03-03 · Class not stated
Archived – Three Lots of Measles, Mumps and Rubella Vaccine Suspended from Use
Communications and Public Affairs Branch · 2007-12-11 · Class not stated
Important Safety Information and availability of Trasylol (aprotinin) - Notice to Hospital
Marketed health products · 2007-11-26 · Class not stated
Important Safety Information on RITUXAN (rituximab) - For Health Professionals
Marketed health products · 2007-08-13 · Class not stated
Archived - Important Safety Information on RITUXAN (rituximab) - Hoffmann-La Roche Limited
Marketed health products · 2007-08-13 · Class not stated
Archived - Association of AVASTIN (bevacizumab) with Tracheo-esophageal Fistula - For Heal
Marketed health products · 2007-06-12 · Class not stated
Archived - Association of AVASTIN® (bevacizumab) with Tracheo-esophageal Fistula - For the
Marketed health products · 2007-06-12 · Class not stated
For Health Professionals - Information Regarding Myozyme (alglucosidase alfa)
Marketed health products · 2007-05-17 · Class not stated
Archived - For Health Professionals - Important safety information and new prescribing inf
Marketed health products · 2007-04-20 · Class not stated
Archived - For the Public - Important safety information and new prescribing information f
Marketed health products · 2007-04-20 · Class not stated
Notice to Hospitals - Association of Trasylol (aprotinin) with hypersensitivity reactions
Marketed health products · 2007-03-30 · Class not stated
Archived - Notice to Hospitals - Increased mortality and risk of serious adverse events wh
Marketed health products · 2006-12-22 · Class not stated
Archived - For Health Professionals - Reports of Bowel Obstruction and Gastrointestinal Pe
Marketed health products · 2006-11-14 · Class not stated
Archived - AVASTIN® (bevacizumab) - Advisories, Warnings and Recalls for the Public
Marketed health products · 2006-10-27 · Class not stated
Archived - For Health Professionals - Association of Avastin (bevacizumab) with hypertensi
Marketed health products · 2006-10-27 · Class not stated
For the Public - Possible Association of Remicade (infliximab) with hepatosplenic T-cell l
Marketed health products · 2006-07-27 · Class not stated
Archived - For Health Professionals - Possible Association of Remicade (infliximab) with h
Marketed health products · 2006-07-27 · Class not stated
Archived - Important Safety Information on Trasylol - Bayer Inc.
Marketed health products · 2006-02-28 · Class not stated
For the Public - Association of WinRho SDF [Rho(D) Immune Globulin (Human)] with Intravasc
Marketed health products · 2006-01-26 · Class not stated
Archived - Notice to Hospitals - Association of WinRho SDF [Rho(D) Immune Globulin (Human)
Marketed health products · 2006-01-26 · Class not stated
Archived - Anti-TNFa Therapy: ENBREL (etanercept), HUMIRA (adalimumab), and REMICADE (infl
Marketed health products · 2006-01-18 · Class not stated
Important Safety Information on anti-TNFα Therapy: ENBREL (etanercept), HUMIRA (adalimumab
Marketed health products · 2006-01-18 · Class not stated
Important Safety Information on the Association of Zevalin (ibritumomab tiuxetan) with sev
Marketed health products · 2005-12-07 · Class not stated
Important Safety Information on the Association of Zevalin (ibritumomab tiuxetan) with sev
Marketed health products · 2005-12-07 · Class not stated
Important Safety Information on the Association of Aranesp (darbepoetin alfa) with pure re
Marketed health products · 2005-11-25 · Class not stated
Archived - Association of Gamunex (Immune globulin intravenous [Human] 10%) with hemolytic
Marketed health products · 2005-10-19 · Class not stated
Association of Gamunex (Immune globulin intravenous [Human] 10%) with hemolytic reactions-
Marketed health products · 2005-10-19 · Class not stated
Association of Xigris (Drotrecogin Alfa Activated) with Mortality in Patients with Single
Marketed health products · 2005-05-09 · Class not stated
Association of Xigris (Drotrecogin Alfa Activated) with Mortality in Patients with Single
Marketed health products · 2005-02-03 · Class not stated
Updated Safety Information on Hematologic Events Associated with HUMIRA and the Risk of In
Marketed health products · 2005-02-02 · Class not stated
Archived - Important safety information on HUMIRA (adalimumab) - Abbott Laboratories, Limi
Marketed health products · 2005-02-01 · Class not stated
Archived - Hepatic Injury Associated with Beta-interferon Treatment for Multiple Sclerosis
Marketed health products · 2003-12-11 · Class not stated
Archived – Important New Safety Information Regarding ZENAPAX (Daclizumab)
Marketed health products · 2003-11-11 · Class not stated
Archived – Use of Kineret®(anakinra) in Combination with Etanercept
Marketed health products · 2002-12-17 · Class not stated
Archived – Thrombotic Events and Immune Globulin Intravenous (IGIV) – Baxter
Marketed health products · 2002-04-12 · Class not stated
Archived - Important Safety Information - EPREX (epoetin alfa) - Janssen-Ortho Inc.
Marketed health products · 2001-11-26 · Class not stated
Archived - Important Drug Warning On Remicadeâ„¢
Marketed health products · 2001-10-23 · Class not stated
Archived - Important Drug Warning - RITUXAN - Hoffmann-La Roche Ltd.
Marketed health products · 2001-05-16 · Class not stated
Archived - Important Drug Warning from the Manufacturer Vitex Inc. on PLAS+®SD
Marketed health products · 2000-10-20 · Class not stated
Archived - Letter to Hospitals Regarding Abbokinase
Marketed health products · 1999-07-23 · Class not stated
Archived - Update Letter to Hospitals Re ABBOKINASE (Urokinase)
Marketed health products · 1999-03-24 · Class not stated
Archived - Letter to Hospitals Re: Abbokinase
Marketed health products · 1999-02-04 · Class not stated
Archived - Notice to Hospitals from the Bureau of Drug Surveillance
Marketed health products · 1998-11-27 · Class not stated
Archived - Notice to hospitals from the Bureau of Drug Surveillance
Marketed health products · 1998-08-07 · Class not stated

Biologic or vaccine by class

Counted from the class recorded on each notice. Blank classes are included.

Biologic or vaccine — notices by classCounted from the class recorded on each notice.0100200300400500Class 1: 6Class 1Class 2: 8Class 2Class 3: 4Class 3Class not stated: 241Class not statSource: Government of Canada Recalls and Safety Alerts open data.

Scroll the chart sideways to see all of it.

Source: Health Canada — Recalls and safety alerts (open data).

Privacy

This site publishes records that governments already publish. It sets no cookie and makes no request to Google unless you accept one. Read more below.

About this record

Every recall notice published by Health Canada: the product, the issue recorded against it, the class assigned, and the official notice itself. A record of what was published, on the date it was published.

Source: Health Canada — Recalls and safety alerts (open data) — Open Government Licence – Canada. Data refreshes daily. Every page links the row it came from.

What this site is not. It is a copy of an official record. It is not a judgement about any business, building or person, and it is not advice. If the record is wrong, the source above is where it is corrected.